BIRC3

Baculoviral IAP repeat-containing protein 3 · Q13489 · BIRC3 on Sugi Atlas →

23,539 patent compounds predicted against BIRC3, 11,256 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydrochloric Acid (SCHEMBL1271981)	0.67	17/20
Hydrochloric Acid (SCHEMBL1273906)	0.67	17/20
SCHEMBL949964	0.55	16/20
SCHEMBL950069	0.80	15/20
SCHEMBL948560	0.56	15/20
SCHEMBL949556	0.60	14/20
SCHEMBL949681	0.59	14/20
SCHEMBL1329088	0.52	14/20
SCHEMBL1273446	0.50	14/20
SCHEMBL1273452	0.50	14/20
Hydrochloric Acid (SCHEMBL1163829)	1.00	13/20
Hydrochloric Acid (SCHEMBL1163960)	1.00	13/20
Hydrochloric Acid (SCHEMBL1164392)	1.00	13/20
Hydrochloric Acid (SCHEMBL1164406)	1.00	13/20
Hydrochloric Acid (SCHEMBL1272094)	1.00	13/20
Hydrochloric Acid (SCHEMBL1272717)	1.00	13/20
Hydrochloric Acid (SCHEMBL1272751)	1.00	13/20
Hydrochloric Acid (SCHEMBL1272925)	1.00	13/20
Hydrochloric Acid (SCHEMBL1273331)	1.00	13/20
Hydrochloric Acid (SCHEMBL1273335)	1.00	13/20

Clinical trials — most relevant to BIRC3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer	PHASE4	UNKNOWN
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis	PHASE2	COMPLETED
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC	PHASE2	COMPLETED
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)	PHASE1/PHASE2	WITHDRAWN
18F-CP18 Imaging Studies for Cancer Treatment With Birinapant	PHASE2	WITHDRAWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	PHASE2	NOT_YET_RECRUITING
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)	PHASE1/PHASE2	COMPLETED
Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma	PHASE1	ACTIVE_NOT_RECRUITING
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma	PHASE1	COMPLETED
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma	PHASE1	COMPLETED
Studying TAK-243 in Patients With Advanced Cancer	PHASE1	RECRUITING
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma	PHASE1	ACTIVE_NOT_RECRUITING
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer	PHASE1	UNKNOWN
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer	PHASE1	COMPLETED
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage	nan	COMPLETED
Dietary Intervention With High Phenolic EVOO in CLL	nan	COMPLETED
Apoptosis Markers in Aggressive Periodontitis	nan	COMPLETED
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases	nan	UNKNOWN
Impact of CASP3 Gene in Chemoresistance	nan	NOT_YET_RECRUITING
Autophagy Bladder Cancer	nan	UNKNOWN
Circulating Markers for Ischemic Heart Disease	nan	RECRUITING
Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer	nan	RECRUITING
MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA	nan	UNKNOWN
A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric Junction	nan	UNKNOWN
Role of Vaspin in Pathophysiology of Pre-eclampsia	nan	UNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Inflammasomes in Cell Death in FTMH, ERM, and RRD	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a BIRC3 binder may also engage these)

Protein	Name	Similarity
Q62210	—	1.000	Q62210 →
Q9R0I6	—	1.000	Q9R0I6 →
BIRC2	Baculoviral IAP repeat-containing protein 2	0.997	landscape →
XIAP	E3 ubiquitin-protein ligase XIAP	0.996	landscape →
Q5BKL8	—	0.995	Q5BKL8 →
A5D8Q0	—	0.995	A5D8Q0 →
A1E2V0	—	0.995	A1E2V0 →
Q90660	—	0.995	Q90660 →
O08863	—	0.994	O08863 →
Q95M72	—	0.993	Q95M72 →
Q95M71	—	0.991	Q95M71 →
O62640	—	0.990	O62640 →
Q60989	—	0.988	Q60989 →
BIRC8	Baculoviral IAP repeat-containing protein 8	0.988	landscape →
P25799	—	0.985	P25799 →
Q9H0M0	—	0.984	Q9H0M0 →
Q24307	—	0.984	Q24307 →
Q9DDT2	—	0.984	Q9DDT2 →
Q9FT70	—	0.983	Q9FT70 →
F4I2Y3	—	0.983	F4I2Y3 →
Q7SIG6	—	0.983	Q7SIG6 →
Q9R016	—	0.982	Q9R016 →
Q24306	—	0.982	Q24306 →
Q4R4A2	—	0.982	Q4R4A2 →
Q28889	—	0.982	Q28889 →
Q6DC02	—	0.982	Q6DC02 →
Q76II0	—	0.982	Q76II0 →
Q8K337	—	0.981	Q8K337 →
Q9LSP8	—	0.981	Q9LSP8 →
F8VPZ3	—	0.981	F8VPZ3 →